MARKET

GLYC

GLYC

GlycoMimetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.375
-0.185
-4.06%
Opening 15:27 01/27 EST
OPEN
4.440
PREV CLOSE
4.560
HIGH
4.495
LOW
4.300
VOLUME
161.56K
TURNOVER
--
52 WEEK HIGH
13.56
52 WEEK LOW
2.640
MARKET CAP
189.70M
P/E (TTM)
-3.3111
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GLYC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GLYC News

  • Week In Review: 4 China Biopharmas Announce $100+ Million Deals In First Week Of 2020
  • Seeking Alpha - Article.01/12 16:22
  • Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
  • American City Business Journals.01/06 22:14
  • Md. biotech outlines path for blood cancer drug, including in China
  • American City Business Journals.01/06 20:02
  • GlycoMimetics out-licenses two programs in Greater China
  • Seeking Alpha - Article.01/06 16:53

More

Industry

Biotechnology & Medical Research
-0.93%
Pharmaceuticals & Medical Research
-0.35%

Hot Stocks

Name
Price
%Change

About GLYC

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
More

Webull offers GlycoMimetics Inc (GLYC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.